… in patients with non–small-cell lung cancer (… gefitinib. One of these mutations, L858R (Leu→Arg),
is also found in NSCLC cell line H3255, which is very sensitive to gefitinib treatment…

… in persons with lung cancer. Many of the principles of management relevant to gefitinib are
distinct … practical guidelines on the use of gefitinib in patients with non–small-cell lung cancer. …

… in ∼50% of patients relapsing after an initial … of a lung cancer patient initially responsive to
gefitinib [13]. Two recent studies revealed amplification of MET oncogene in ∼20% of patients …

… lung cancer samples from US patients who responded to gefitinib therapy and in a lung
adenocarcinoma cell … inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. …

… This review discusses the use of gefitinib in Asian patients with advanced NSCLC using
the extensive clinical data available and also summarizes data on the discovery of the EGFR …

… In conclusion, gefitinib treatment as first-line therapy for advanced NSCLC with EGFR
mutations demonstrated promising activity and a good toxicity profile. Randomised phase III trials …

… Increased anticoagulation effects and/or bleeding events have been reported in some
patients taking warfarin while on gefitinib therapy. Patients taking warfarin should therefore be …

… gefitinib is interstitial lung disease (ILD). The Iressa dose evaluation for advanced lung
cancer … single agent gefitinib, 250 or 500 mg orally per day in pretreated patients with non-small …

… in selecting therapy for subsets of patients with lung cancer. In summary, gefitinib has provided
an … disease NSCLC patients, and it is likely that there will be increasing use of first-line …

… of gefitinib therapy in patients enrolled in the EAP at the Medical Oncology Department of …
Our results provide further data about gefitinib therapy in the expanded access program for …